Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

25 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Secukinumab treatment of moderate to severe plaque psoriasis in routine clinical care: real-life data of prior and concomitant use of psoriasis treatments from the PROSPECT study.
Körber A, Thaçi D, von Kiedrowski R, Bachhuber T, Melzer N, Kasparek T, Kraehn-Senftleben G, Amon U, Augustin M. Körber A, et al. Among authors: bachhuber t. J Eur Acad Dermatol Venereol. 2018 Mar;32(3):411-419. doi: 10.1111/jdv.14604. Epub 2017 Nov 22. J Eur Acad Dermatol Venereol. 2018. PMID: 28960469
Secukinumab treatment leads to normalization of quality of life and disease symptoms in psoriasis patients with or without prior systemic psoriasis therapy: the PROSE study results.
Augustin M, Dauden E, Mrowietz U, Konstantinou MP, Gerdes S, Kingo K, Szepietowski JC, Perrot JL, Cuccia A, Rissler M, Gathmann S, Sieder C, Orsenigo R, Jagiello P, Bachhuber T. Augustin M, et al. Among authors: bachhuber t. J Eur Acad Dermatol Venereol. 2021 Feb;35(2):431-440. doi: 10.1111/jdv.16632. Epub 2020 Jul 1. J Eur Acad Dermatol Venereol. 2021. PMID: 32426889
Secukinumab effects on disease burden, patient needs and benefits, and treatment satisfaction in patients with plaque psoriasis across European regions: patient perspective data from the PROSE study.
da Silva N, Sommer R, Ortmann CE, Jagiello P, Bachhuber T, Augustin M. da Silva N, et al. Among authors: bachhuber t. J Eur Acad Dermatol Venereol. 2021 Nov;35(11):2241-2249. doi: 10.1111/jdv.17525. Epub 2021 Jul 31. J Eur Acad Dermatol Venereol. 2021. PMID: 34273904
International Hidradenitis Suppurativa Severity Scoring System (IHS4) as a holistic measure of hidradenitis suppurativa disease severity compared with Hurley staging: A post hoc analysis of the SUNRISE and SUNSHINE phase 3 trials of secukinumab.
Zouboulis CC, Prens EP, Sayed CJ, Molina-Leyva A, Bettoli V, Romanelli M, Szepietowski JC, Martinez AL, Kasparek T, Lobach I, Wozniak MB, Ortmann CE, Thomas N, Bachhuber T, Ravichandran S, Tzellos T. Zouboulis CC, et al. Among authors: bachhuber t. J Eur Acad Dermatol Venereol. 2024 Jun;38(6):e496-e499. doi: 10.1111/jdv.19681. Epub 2023 Dec 6. J Eur Acad Dermatol Venereol. 2024. PMID: 38058224 Clinical Trial. No abstract available.
Secukinumab efficacy in patients with hidradenitis suppurativa assessed by the International Hidradenitis Suppurativa Severity Score System (IHS4): A post hoc analysis of the SUNSHINE and SUNRISE trials.
Zouboulis CC, Kyrgidis A, Alavi A, Jemec GBE, Martorell A, Marzano AV, van der Zee HH, Wozniak MB, Martinez AL, Kasparek T, Bachhuber T, Ortmann CE, Lobach I, Thomas N, Ravichandran S, Tzellos T. Zouboulis CC, et al. Among authors: bachhuber t. J Eur Acad Dermatol Venereol. 2024 Oct 19. doi: 10.1111/jdv.20369. Online ahead of print. J Eur Acad Dermatol Venereol. 2024. PMID: 39425517
25 results